All In Biotech

Drug Trial Radar · NCT05724693

Study of Bemnifosbuvir in Subjects With Normal and Impaired Hepatic Function

A Phase 1, Multicenter, Open-Label, Parallel-Group, Pharmacokinetic Single Dose Study of Bemnifosbuvir (AT-527) in Adult Subjects With Normal and Impaired Hepatic Function

Last checked: Nov 20, 2026Latest source record: Jul 31, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

39

Actual

Start

Jan 30, 2023

Primary completion

Apr 23, 2024

Study completion Apr 23, 2024

Sponsor

Lead sponsor
Atea Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Feb 13, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

To Assess the Effect of Hepatic Impairment on the Pharmacokinetics of Bemnifosbuvir After a Single Dose

Conditions

  • Healthy Volunteer
  • Hepatic Impairment

Interventions

  • Bemnifosbuvir (BEM)Drug

    Day 1: A single dose of BEM will be administered

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pharmacokinetics (PK) of BEM Maximum plasma concentration (Cmax)Time frame: Day 1
  2. Pharmacokinetics (PK) of BEM Area under the plasma concentration-time curve (AUC)Time frame: Day 1
  3. Pharmacokinetics (PK) of BEM AUCTime frame: Day 1

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Atea Study Site Orlando Clinical Research Center

    Orlando, Florida

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.